Stoic Venture Capital takes holding in nanotech Ferronova

Stoic Venture Capital

Stoic Venture Capital has taken part in a $3.5m Series A funding round for Australian biotechnology company Ferronova Pty Ltd.

The funding round was led by Uniseed, where Stoic Venture Capital is the co-investment fund. Uniseed is a commercialisation fund which focuses on financing early-stage companies that emerge from member universities.

Ferronova’s technology has the potential to transform care for early stage cancer patients in complex cancers such as colorectal cancer. The company originated from landmark research by the Victoria University of Wellington and the University of South Australia.

Stoic Venture Capital Partner Geoff Waring said the venture capital fund’s portfolio expanded dramatically to a total of 17 companies in the past two years with a primary focus on healthcare.

“Ferronova is a visionary Australian company with technology solutions that are advancing the detection, diagnosis and treatment of early stage cancer,” Dr Waring said.

“We support the growth of healthcare companies that are changing outcomes and improving the lives of patients.”

Dr Waring said Stoic Venture Capital would continue to have a big allocation to healthcare opportunities.

“Healthcare remains a resilient and high potential asset class. Evidence-backed medical technology creates alternative models of care and prevention.”

“Importantly, our investments are also contributing to the pioneering of new research and development in medicine and science to help more patients in the future.”

About Stoic Venture Capital

Stoic Venture Capital provides financing for early-stage companies, particularly those arising from university research. We are unconditionally registered as an Early Stage Venture Capital Limited Partnership (ESVCLP). We take a collaborative approach to investing in the highest potential companies.

/Public Release.